University of California, Los Angeles
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of California, Los Angeles sits in the top decile of US sponsors by registered trial count (#37 of 15,742 sponsors by registered trial count).
University of California, Los Angeles: 897 sponsored US clinical trials, 158 recruiting.
University of California, Los Angeles sponsors 897 registered US clinical trials on ClinicalTrials.gov, 158 of them currently recruiting, and 622 completed. 98 of these trials are in Phase 3-4 (later-stage) and 194 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 17 trials.
Top-decile sponsor footprint
University of California, Los Angeles ranks in the top decile of sponsors by registered trial count (#37 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
622 of 679 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
897 total, page 6 of 18
Micro-Randomized Trial to Optimize Digital Oral Health Behavior Change Interventions
NCT05624489
Novel Index (PIMR) in PAH
NCT05812976
Comparing Perclose to Statseal With Perclose in Transcatheter Aortic Valve Replacement Arteriotomy Closure
NCT05637970
PIMR and Pulmonary Vascular Disease
NCT05843461
Healthcare Providers as Trusted Messengers to Increase Receipt of Tax Credits Among Low-income Families
NCT05612685
Percutaneous Endoluminal Benign Biliary Laser
NCT05567003
Investigating LIFUP in Anhedonic Depression
NCT06285474
Adaptive Intervention to Facilitate PrEP Uptake/Adherence Among Transgender Women
NCT05016232
Effects of Prompt to Bundle COVID-19 Booster and Flu Shot
NCT05586165
Information Provision and Consistency Framing to Increase COVID-19 Booster Uptake
NCT05586178
Boost Intentions and Facilitate Action to Promote COVID-19 Booster Take-up
NCT05586204
Testing a Scalable Model For ACEs-Related Care Navigation
NCT05567250
A Latino MSM Focused Pre-Exposure Prophylaxis Uptake Intervention
NCT05434390
Virtual Reality-Reward Training for Anhedonia
NCT05342077
Patient Portal Flu Vaccine Reminders_RCT 5 (LADHS)
NCT05535777
Patient Portal Flu Vaccine Reminders (5)
NCT05525494
Evaluation of Smoked THC and CBD in Men and Women
NCT05037487
Dopaminergic Enhancement of Rehabilitation Therapy Early After Stroke
NCT05369533
Remote Assessment and Intervention for Behavior Problems in Kids With TSC
NCT06311474
LIFUP for Treatment of Motor Deficits in Parkinson's Disease
NCT04593875
Postoperative Opt-In Narcotics Treatment in Breast
NCT05078398
Corneal Nerves After Treatment With Cenegermin
NCT04627571
Endothelin-1 and Cardiac Allograft Vasculopathy (CAV)
NCT05373108
Cannabidiol Effects on Craving and Relapse Prevention in Opioid Use Disorder
NCT03787628
Brain Changes in Pediatric OSA
NCT05368077
Daily Habits & Consumer Preferences Study
NCT05402137
An Open Label Study in Adults to Test the Efficacy of Mitoquinone/Mitoquinol Mesylate to Prevent Severe Viral Illness
NCT05381454
Metformin Treatment in Progressive Multiple Sclerosis
NCT05349474
Mindfulness Meditation Neuroimaging Study for Undergraduates
NCT05304052
Cortisol and Food Insecurity
NCT05191030
High-Dose Moderna mRNA-1273 Booster Study for Lung Transplant Recipients
NCT05280158
Acute Normovolemic Hemodilution in Complex Cardiac Surgery
NCT05049590
The Impact of Choice on Colorectal Cancer Screening
NCT05275530
Increasing Engagement With Messages Regarding CRC Screening Among Adults Aged 45-49
NCT05281159
Applying Best Clinical Practices to Patients at High Risk of Respiratory Complications
NCT04263363
Antibacterial Mouthwash for Pharyngeal Gonorrhea Prevention
NCT04966507
Inflammation and Daily Life Study
NCT03771612
Orthodontic Varnish Microbiology Study
NCT04528134
Bereaved Young Adults Study
NCT05352243
TEST-ON - Does iStim Reduce Urinary Urgency?
NCT04957524
Sex Differences in Effectiveness of CBT on IBS Project 3
NCT05155631
Virtual Reality Experience for Stress Reduction in Cardiology Patients
NCT04984655
Affect Treatment for Depression and Anxiety
NCT05203861
An Inflammatory Challenge Using Endotoxin
NCT04310423
Patient Portal Flu Vaccine Reminders_RCT 4
NCT05052190
App-Based Mindfulness Meditation for People of Color Who Experience Race-Related Stress
NCT05027113
Intergenerational Transmission of Traumatic Stress
NCT05264415
Therapeutic Response of Cannabidiol in Rheumatoid Arthritis
NCT04911127
Evaluating Quality and Value of US Ambulatory Care Delivered Among Medicaid Expansion/Non-Expansion States, 2012-2015
NCT05319743
A Dyadic Telehealth Program for Alzheimer's Patients/Caregivers
NCT05102565
What is open in the University of California, Los Angeles pipeline
158 recruiting of 897 indexed (18% open); 622 completed (69%).
Phase mix: 98 late (III/IV) vs 194 early (I/II) (early-phase heavy).
Top condition: Depression (17 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of California, Los Angeles: open-pipeline peers nationwide
Peers matched on 897 registered trials and 18% open enrollment, not the therapeutic-area sidebar.
University of California, Los Angeles sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 897 trials (± recruiting share)
- Indiana University · 890 trials · 18% recruiting
- Hoffmann-La Roche · 909 trials · 8% recruiting
- Brigham and Women's Hospital · 937 trials · 15% recruiting
- University of Texas Southwestern Medical Center · 837 trials · 19% recruiting
Sponsors near 18% open enrollment (± trial volume)
- ConvaTec · 18% recruiting · 17 trials
- Endologix · 18% recruiting · 17 trials
- National Institute on Deafness and Other Communication Disorders (NIDCD) · 18% recruiting · 34 trials
- NICHD Pelvic Floor Disorders Network · 18% recruiting · 17 trials
Related
What to do with this University of California, Los Angeles page
897 registered trials is a research-attention snapshot, not an endorsement of University of California, Los Angeles or any single study.
- 158 of University of California, Los Angeles's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Depression is the condition University of California, Los Angeles studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Depression trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of California, Los Angeles pipeline card: 897 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.